Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction. The impairments in diastolic relaxation are especially pronounce...

Source: Cardiovascular Diabetology - January 13, 2017 Category: Cardiology Authors: Javad Habibi, Annayya R. Aroor, James R. Sowers, Guanghong Jia, Melvin R. Hayden, Mona Garro, Brady Barron, Eric Mayoux, R. Scott Rector, Adam Whaley-Connell and Vincent G. DeMarco Source Type: research